Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma
Background This study was conducted to assess the clinical and prognostic significance of lack of CD15 expression, proliferative index (PI), and expression of tumor suppressor protein p53 in pediatric classical Hodgkin lymphoma (CHL). Procedure Pre‐treatment lymph node (LN) biopsies were studied by...
Gespeichert in:
| Veröffentlicht in: | Pediatric Blood & Cancer 2008-02, Vol.50 (2), p.280-283 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 283 |
|---|---|
| container_issue | 2 |
| container_start_page | 280 |
| container_title | Pediatric Blood & Cancer |
| container_volume | 50 |
| creator | Dinand, Veronique Malik, Ajay Unni, Rajani Arya, Laxman S. Pandey, R.M. Dawar, Ramesh |
| description | Background
This study was conducted to assess the clinical and prognostic significance of lack of CD15 expression, proliferative index (PI), and expression of tumor suppressor protein p53 in pediatric classical Hodgkin lymphoma (CHL).
Procedure
Pre‐treatment lymph node (LN) biopsies were studied by immunohistochemistry for immunophenotyping of the lymphoma and with Ki‐67 (PI) and p53 antibodies. Expression of CD15 antigen on the Hodgkin and Reed‐Sternberg (H‐RS) cells, proliferation, and apoptosis parameters were correlated with clinical stage, response to chemotherapy alone, overall (OS) and failure‐free survival (FFS).
Results
One hundred and twenty‐one children with CHL were studied. Expression of Ki‐67 and p53 in H‐RS cells was seen in 100% and 89.9% of the cases, respectively. Loss of CD15 expression, seen in 12 (9.9%) cases, was significantly associated with p53 negativity and was an independent prognostic factor for poor OS and poor FFS. PI ≤ 74% was an independent prognostic factor for poor FFS.
Conclusions
Loss of CD15 expression in CHL might be related to p53 dysregulation. High PI in HL might reflect a high level of endomitosis within tumor cells, and could lead to higher sensitivity to chemotherapy. Low pre‐treatment PI and lack of CD15 expression were found to be predictive factors for poor FFS in pediatric CHL. Pediatr Blood Cancer 2008;50:280–283. © 2007 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/pbc.21204 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20620119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20620119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4584-2562ed969722599f4816729ce4bd61fdd894813b246c4814d3809f779f1446c03</originalsourceid><addsrcrecordid>eNp1kMFPwjAUxhujEUQP_gNmJxMPg7Zrt_WoKCAhwgHl2HRtp5WNzXYo_PdWQT15ei_f93tfXj4AzhHsIghxr85kFyMMyQFoI0poSCFKDn93yFrgxLlXj8aQpseghRKCkoTRNpjObFWYXFvRmHcdmJXSm0CsVNC_RTTQm9pq50y18k5Qa2VEY40MZCG8KkURjCr1vPResS3rl6oUp-AoF4XTZ_vZAY-Du3l_FE6mw_v-9SSUhKYkxDTGWrGYJRhTxnKSojjBTGqSqRjlSqXMS1GGSSz9QlSUQpb7l3NEvASjDrjc5da2eltr1_DSOKmLQqx0tXYcwxhDhJgHr3agtJVzVue8tqYUdssR5F_tcd8e_27Psxf70HVWavVH7uvyQG8HfJhCb_9P4rOb_k9kuLswrtGb3wthlzxOooTyxcOQT8bRfDxYjPhT9AlKIoaG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20620119</pqid></control><display><type>article</type><title>Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Dinand, Veronique ; Malik, Ajay ; Unni, Rajani ; Arya, Laxman S. ; Pandey, R.M. ; Dawar, Ramesh</creator><creatorcontrib>Dinand, Veronique ; Malik, Ajay ; Unni, Rajani ; Arya, Laxman S. ; Pandey, R.M. ; Dawar, Ramesh</creatorcontrib><description>Background
This study was conducted to assess the clinical and prognostic significance of lack of CD15 expression, proliferative index (PI), and expression of tumor suppressor protein p53 in pediatric classical Hodgkin lymphoma (CHL).
Procedure
Pre‐treatment lymph node (LN) biopsies were studied by immunohistochemistry for immunophenotyping of the lymphoma and with Ki‐67 (PI) and p53 antibodies. Expression of CD15 antigen on the Hodgkin and Reed‐Sternberg (H‐RS) cells, proliferation, and apoptosis parameters were correlated with clinical stage, response to chemotherapy alone, overall (OS) and failure‐free survival (FFS).
Results
One hundred and twenty‐one children with CHL were studied. Expression of Ki‐67 and p53 in H‐RS cells was seen in 100% and 89.9% of the cases, respectively. Loss of CD15 expression, seen in 12 (9.9%) cases, was significantly associated with p53 negativity and was an independent prognostic factor for poor OS and poor FFS. PI ≤ 74% was an independent prognostic factor for poor FFS.
Conclusions
Loss of CD15 expression in CHL might be related to p53 dysregulation. High PI in HL might reflect a high level of endomitosis within tumor cells, and could lead to higher sensitivity to chemotherapy. Low pre‐treatment PI and lack of CD15 expression were found to be predictive factors for poor FFS in pediatric CHL. Pediatr Blood Cancer 2008;50:280–283. © 2007 Wiley‐Liss, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/pbc.21204</identifier><identifier>PMID: 17417795</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject><![CDATA[Adolescent ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; apoptosis ; Bleomycin - administration & dosage ; Cell Growth Processes - physiology ; Child ; Child, Preschool ; children ; Cyclophosphamide - administration & dosage ; Dacarbazine - administration & dosage ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Female ; Hodgkin Disease - drug therapy ; Hodgkin Disease - immunology ; Hodgkin Disease - metabolism ; Hodgkin Disease - pathology ; Hodgkin lymphoma ; Humans ; Immunophenotyping ; Kaplan-Meier Estimate ; Ki-67 Antigen - biosynthesis ; Lewis X Antigen - biosynthesis ; Male ; Neoplasm Staging ; Prednisone - administration & dosage ; Procarbazine - administration & dosage ; proliferation ; Retrospective Studies ; treatment outcome ; Tumor Suppressor Protein p53 - biosynthesis ; Vinblastine - administration & dosage ; Vincristine - administration & dosage]]></subject><ispartof>Pediatric Blood & Cancer, 2008-02, Vol.50 (2), p.280-283</ispartof><rights>Copyright © 2007 Wiley‐Liss, Inc.</rights><rights>(c) 2007 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4584-2562ed969722599f4816729ce4bd61fdd894813b246c4814d3809f779f1446c03</citedby><cites>FETCH-LOGICAL-c4584-2562ed969722599f4816729ce4bd61fdd894813b246c4814d3809f779f1446c03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.21204$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.21204$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17417795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dinand, Veronique</creatorcontrib><creatorcontrib>Malik, Ajay</creatorcontrib><creatorcontrib>Unni, Rajani</creatorcontrib><creatorcontrib>Arya, Laxman S.</creatorcontrib><creatorcontrib>Pandey, R.M.</creatorcontrib><creatorcontrib>Dawar, Ramesh</creatorcontrib><title>Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma</title><title>Pediatric Blood & Cancer</title><addtitle>Pediatr. Blood Cancer</addtitle><description>Background
This study was conducted to assess the clinical and prognostic significance of lack of CD15 expression, proliferative index (PI), and expression of tumor suppressor protein p53 in pediatric classical Hodgkin lymphoma (CHL).
Procedure
Pre‐treatment lymph node (LN) biopsies were studied by immunohistochemistry for immunophenotyping of the lymphoma and with Ki‐67 (PI) and p53 antibodies. Expression of CD15 antigen on the Hodgkin and Reed‐Sternberg (H‐RS) cells, proliferation, and apoptosis parameters were correlated with clinical stage, response to chemotherapy alone, overall (OS) and failure‐free survival (FFS).
Results
One hundred and twenty‐one children with CHL were studied. Expression of Ki‐67 and p53 in H‐RS cells was seen in 100% and 89.9% of the cases, respectively. Loss of CD15 expression, seen in 12 (9.9%) cases, was significantly associated with p53 negativity and was an independent prognostic factor for poor OS and poor FFS. PI ≤ 74% was an independent prognostic factor for poor FFS.
Conclusions
Loss of CD15 expression in CHL might be related to p53 dysregulation. High PI in HL might reflect a high level of endomitosis within tumor cells, and could lead to higher sensitivity to chemotherapy. Low pre‐treatment PI and lack of CD15 expression were found to be predictive factors for poor FFS in pediatric CHL. Pediatr Blood Cancer 2008;50:280–283. © 2007 Wiley‐Liss, Inc.</description><subject>Adolescent</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>apoptosis</subject><subject>Bleomycin - administration & dosage</subject><subject>Cell Growth Processes - physiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>children</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Dacarbazine - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - immunology</subject><subject>Hodgkin Disease - metabolism</subject><subject>Hodgkin Disease - pathology</subject><subject>Hodgkin lymphoma</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>Kaplan-Meier Estimate</subject><subject>Ki-67 Antigen - biosynthesis</subject><subject>Lewis X Antigen - biosynthesis</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Prednisone - administration & dosage</subject><subject>Procarbazine - administration & dosage</subject><subject>proliferation</subject><subject>Retrospective Studies</subject><subject>treatment outcome</subject><subject>Tumor Suppressor Protein p53 - biosynthesis</subject><subject>Vinblastine - administration & dosage</subject><subject>Vincristine - administration & dosage</subject><issn>1545-5009</issn><issn>1545-5017</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFPwjAUxhujEUQP_gNmJxMPg7Zrt_WoKCAhwgHl2HRtp5WNzXYo_PdWQT15ei_f93tfXj4AzhHsIghxr85kFyMMyQFoI0poSCFKDn93yFrgxLlXj8aQpseghRKCkoTRNpjObFWYXFvRmHcdmJXSm0CsVNC_RTTQm9pq50y18k5Qa2VEY40MZCG8KkURjCr1vPResS3rl6oUp-AoF4XTZ_vZAY-Du3l_FE6mw_v-9SSUhKYkxDTGWrGYJRhTxnKSojjBTGqSqRjlSqXMS1GGSSz9QlSUQpb7l3NEvASjDrjc5da2eltr1_DSOKmLQqx0tXYcwxhDhJgHr3agtJVzVue8tqYUdssR5F_tcd8e_27Psxf70HVWavVH7uvyQG8HfJhCb_9P4rOb_k9kuLswrtGb3wthlzxOooTyxcOQT8bRfDxYjPhT9AlKIoaG</recordid><startdate>200802</startdate><enddate>200802</enddate><creator>Dinand, Veronique</creator><creator>Malik, Ajay</creator><creator>Unni, Rajani</creator><creator>Arya, Laxman S.</creator><creator>Pandey, R.M.</creator><creator>Dawar, Ramesh</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>200802</creationdate><title>Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma</title><author>Dinand, Veronique ; Malik, Ajay ; Unni, Rajani ; Arya, Laxman S. ; Pandey, R.M. ; Dawar, Ramesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4584-2562ed969722599f4816729ce4bd61fdd894813b246c4814d3809f779f1446c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>apoptosis</topic><topic>Bleomycin - administration & dosage</topic><topic>Cell Growth Processes - physiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>children</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Dacarbazine - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - immunology</topic><topic>Hodgkin Disease - metabolism</topic><topic>Hodgkin Disease - pathology</topic><topic>Hodgkin lymphoma</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>Kaplan-Meier Estimate</topic><topic>Ki-67 Antigen - biosynthesis</topic><topic>Lewis X Antigen - biosynthesis</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Prednisone - administration & dosage</topic><topic>Procarbazine - administration & dosage</topic><topic>proliferation</topic><topic>Retrospective Studies</topic><topic>treatment outcome</topic><topic>Tumor Suppressor Protein p53 - biosynthesis</topic><topic>Vinblastine - administration & dosage</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dinand, Veronique</creatorcontrib><creatorcontrib>Malik, Ajay</creatorcontrib><creatorcontrib>Unni, Rajani</creatorcontrib><creatorcontrib>Arya, Laxman S.</creatorcontrib><creatorcontrib>Pandey, R.M.</creatorcontrib><creatorcontrib>Dawar, Ramesh</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Pediatric Blood & Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dinand, Veronique</au><au>Malik, Ajay</au><au>Unni, Rajani</au><au>Arya, Laxman S.</au><au>Pandey, R.M.</au><au>Dawar, Ramesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma</atitle><jtitle>Pediatric Blood & Cancer</jtitle><addtitle>Pediatr. Blood Cancer</addtitle><date>2008-02</date><risdate>2008</risdate><volume>50</volume><issue>2</issue><spage>280</spage><epage>283</epage><pages>280-283</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><eissn>1096-911X</eissn><abstract>Background
This study was conducted to assess the clinical and prognostic significance of lack of CD15 expression, proliferative index (PI), and expression of tumor suppressor protein p53 in pediatric classical Hodgkin lymphoma (CHL).
Procedure
Pre‐treatment lymph node (LN) biopsies were studied by immunohistochemistry for immunophenotyping of the lymphoma and with Ki‐67 (PI) and p53 antibodies. Expression of CD15 antigen on the Hodgkin and Reed‐Sternberg (H‐RS) cells, proliferation, and apoptosis parameters were correlated with clinical stage, response to chemotherapy alone, overall (OS) and failure‐free survival (FFS).
Results
One hundred and twenty‐one children with CHL were studied. Expression of Ki‐67 and p53 in H‐RS cells was seen in 100% and 89.9% of the cases, respectively. Loss of CD15 expression, seen in 12 (9.9%) cases, was significantly associated with p53 negativity and was an independent prognostic factor for poor OS and poor FFS. PI ≤ 74% was an independent prognostic factor for poor FFS.
Conclusions
Loss of CD15 expression in CHL might be related to p53 dysregulation. High PI in HL might reflect a high level of endomitosis within tumor cells, and could lead to higher sensitivity to chemotherapy. Low pre‐treatment PI and lack of CD15 expression were found to be predictive factors for poor FFS in pediatric CHL. Pediatr Blood Cancer 2008;50:280–283. © 2007 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17417795</pmid><doi>10.1002/pbc.21204</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric Blood & Cancer, 2008-02, Vol.50 (2), p.280-283 |
| issn | 1545-5009 1545-5017 1096-911X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20620119 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adolescent Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use apoptosis Bleomycin - administration & dosage Cell Growth Processes - physiology Child Child, Preschool children Cyclophosphamide - administration & dosage Dacarbazine - administration & dosage Disease-Free Survival Doxorubicin - administration & dosage Female Hodgkin Disease - drug therapy Hodgkin Disease - immunology Hodgkin Disease - metabolism Hodgkin Disease - pathology Hodgkin lymphoma Humans Immunophenotyping Kaplan-Meier Estimate Ki-67 Antigen - biosynthesis Lewis X Antigen - biosynthesis Male Neoplasm Staging Prednisone - administration & dosage Procarbazine - administration & dosage proliferation Retrospective Studies treatment outcome Tumor Suppressor Protein p53 - biosynthesis Vinblastine - administration & dosage Vincristine - administration & dosage |
| title | Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A38%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proliferative%20index%20and%20CD15%20expression%20in%20pediatric%20classical%20Hodgkin%20lymphoma&rft.jtitle=Pediatric%20Blood%20&%20Cancer&rft.au=Dinand,%20Veronique&rft.date=2008-02&rft.volume=50&rft.issue=2&rft.spage=280&rft.epage=283&rft.pages=280-283&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.21204&rft_dat=%3Cproquest_cross%3E20620119%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20620119&rft_id=info:pmid/17417795&rfr_iscdi=true |